Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Eliana S Armstrong

Showing results (1-10 of 13) with videos related to

Pageof 2
Sort By:
Current Opinion in Microbiology|October 12, 2010
Combating evolution with intelligent design: the neoglycoside ACHN-490Eliana S Armstrong, George H Miller
Antimicrobial Agents and Chemotherapy|November 11, 2015
In Vitro Activity of Ceftolozane-Tazobactam against Anaerobic Organisms Identified during the ASPECT-cIAI StudyEliana S Armstrong, David J Farrell, Melissa Palchak, et al.
Antimicrobial Agents and Chemotherapy|January 31, 2018
A Multicenter, Randomized, Double-Blind, Phase 2 Study of the Efficacy and Safety of Plazomicin Compared with Levofloxacin in the Treatment of Complicated Urinary Tract Infection and Acute PyelonephritisLynn E Connolly, Valerie Riddle, Deborah Cebrik, et al.
Antimicrobial Agents and Chemotherapy|March 19, 2008
Detection of methyltransferases conferring high-level resistance to aminoglycosides in enterobacteriaceae from Europe, North America, and Latin AmericaThomas R Fritsche, Mariana Castanheira, George H Miller, et al.
Organic Letters|November 17, 2011
Hybrid aminoglycoside antibiotics via Tsuji palladium-catalyzed allylic deoxygenationStephen Hanessian, Juan Pablo Maianti, Rowena D Matias, et al.
BMC Infectious Diseases|November 27, 2016
Outcomes of high-dose levofloxacin therapy remain bound to the levofloxacin minimum inhibitory concentration in complicated urinary tract infectionsEliana S Armstrong, Janelle A Mikulca, Daniel J Cloutier, et al.
Antimicrobial Agents and Chemotherapy|February 2, 2011
Activity of ACHN-490 tested alone and in combination with other agents against Pseudomonas aeruginosaGlenn A Pankuch, Gengrong Lin, Aya Kubo, et al.
International Journal of Antimicrobial Agents|August 9, 2011
Activity of ACHN-490 against meticillin-resistant Staphylococcus aureus (MRSA) isolates from patients in US hospitalsFred C Tenover, Isabella Tickler, Eliana S Armstrong, et al.
Antimicrobial Agents and Chemotherapy|September 23, 2009
ACHN-490, a neoglycoside with potent in vitro activity against multidrug-resistant Klebsiella pneumoniae isolatesAndrea Endimiani, Kristine M Hujer, Andrea M Hujer, et al.
Applied and Environmental Microbiology|May 3, 2011
BTI1, an azoreductase with pH-dependent substrate specificityHans E Johansson, Mary K Johansson, Albert C Wong, et al.
Pageof 2

Showing results (1-10 of 13) with videos related to

Sort By:
Pageof 2
Current Opinion in Microbiology|October 12, 2010
Combating evolution with intelligent design: the neoglycoside ACHN-490Eliana S Armstrong, George H Miller
Antimicrobial Agents and Chemotherapy|November 11, 2015
In Vitro Activity of Ceftolozane-Tazobactam against Anaerobic Organisms Identified during the ASPECT-cIAI StudyEliana S Armstrong, David J Farrell, Melissa Palchak, et al.
Antimicrobial Agents and Chemotherapy|January 31, 2018
A Multicenter, Randomized, Double-Blind, Phase 2 Study of the Efficacy and Safety of Plazomicin Compared with Levofloxacin in the Treatment of Complicated Urinary Tract Infection and Acute PyelonephritisLynn E Connolly, Valerie Riddle, Deborah Cebrik, et al.
Antimicrobial Agents and Chemotherapy|March 19, 2008
Detection of methyltransferases conferring high-level resistance to aminoglycosides in enterobacteriaceae from Europe, North America, and Latin AmericaThomas R Fritsche, Mariana Castanheira, George H Miller, et al.
Organic Letters|November 17, 2011
Hybrid aminoglycoside antibiotics via Tsuji palladium-catalyzed allylic deoxygenationStephen Hanessian, Juan Pablo Maianti, Rowena D Matias, et al.
BMC Infectious Diseases|November 27, 2016
Outcomes of high-dose levofloxacin therapy remain bound to the levofloxacin minimum inhibitory concentration in complicated urinary tract infectionsEliana S Armstrong, Janelle A Mikulca, Daniel J Cloutier, et al.
Antimicrobial Agents and Chemotherapy|February 2, 2011
Activity of ACHN-490 tested alone and in combination with other agents against Pseudomonas aeruginosaGlenn A Pankuch, Gengrong Lin, Aya Kubo, et al.
International Journal of Antimicrobial Agents|August 9, 2011
Activity of ACHN-490 against meticillin-resistant Staphylococcus aureus (MRSA) isolates from patients in US hospitalsFred C Tenover, Isabella Tickler, Eliana S Armstrong, et al.
Antimicrobial Agents and Chemotherapy|September 23, 2009
ACHN-490, a neoglycoside with potent in vitro activity against multidrug-resistant Klebsiella pneumoniae isolatesAndrea Endimiani, Kristine M Hujer, Andrea M Hujer, et al.
Applied and Environmental Microbiology|May 3, 2011
BTI1, an azoreductase with pH-dependent substrate specificityHans E Johansson, Mary K Johansson, Albert C Wong, et al.
Pageof 2